(b)(4).The absorb device is currently not commercially available in the u.S.; however, it is similar to a device sold in the us.The device was not returned for evaluation.A review of the lot history record and complaint history could not be conducted because the lot numbers were not provided.The reported patient effect of aneurysm, as listed in the bioresorbable vascular scaffold (bvs) system, absorb, instructions for use (ifu), is a known adverse event associated with the use of a coronary scaffold in native coronary arteries.Based on the information reviewed, there is no indication of a product quality issue with respect to manufacture, design or labeling.Based on the case information and related record review, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.
|
It was reported that the procedure on (b)(6) 2013 was to treat a lesion in the proximal circumflex.Pre-dilatation was done with 2.0x12mm and 2.5x12mm balloons.A 2.5x18mm absorb scaffold was implanted and post-dilated with a 3.0x8mm non-compliant balloon at 18 atmospheres.The patient returned on (b)(6) 2016, aysmptomatic, to check progress in the left anterior descending artery.Optical coherence tomography (oct) control angio was done and an aneurysm was observed at the site of the scaffold.There was no treatment performed.No additional information was provided.
|